72It follows that that the concept of a ‘global marketing authorisation’, within the meaning of the second subparagraph of Article 6(1) of Directive 2001/83, covers all subsequent developments of the original medicinal product, irrespective of their authorisation procedures, namely through the variation of the initial MA for that medicinal product or through the grant of a separate MA.
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.